Is induced pluripotent stem cell therapy safe for clinical use?

What is the biggest safety risk with iPSC therapy?

The primary safety concern is that undifferentiated iPSCs—cells that haven't yet turned into the desired cell type—can form teratomas, a type of benign tumor, after transplantation. A 2021 study directly addressed this by showing that treating iPSC-derived beta cells (for diabetes) with a drug called Brentuximab vedotin, which targets a marker (CD30) found only on undifferentiated cells, eliminated teratoma formation in mice [2]. In that study, untreated cells consistently formed teratomas, while treated cells did not, and the treatment did not harm the function of the desired beta cells [2]. This suggests a practical way to greatly reduce a major safety hurdle.

What do the animal studies tell us about safety and effectiveness?

Animal studies consistently show that iPSC therapy can be effective, but safety data is mixed and depends on the specific application. A large 2024 meta-analysis of 51 animal studies (over 1,000 animals) using iPSC-derived heart cells for ischemic heart disease found that the treatment improved heart function (ejection fraction by about 8%) and did not increase the risk of death or dangerous heart rhythms compared to controls [1]. This is reassuring for cardiac use. However, a 2025 pre-clinical study for Parkinson's disease, which used rigorous Good Laboratory Practice standards, found that while all cell lines met safety criteria, cells from one patient out of four failed to improve movement in rats, showing that effectiveness can vary from person to person even when safety is acceptable [3]. A 2025 systematic review of iPSC therapy for traumatic brain injury in rodents also reported significant improvements in movement, thinking, and social behavior, with cells migrating to injury sites and reducing lesion size [4].

Why isn't iPSC therapy ready for widespread clinical use yet?

Despite promising results in animals, there is a significant gap between pre-clinical promise and proven human safety. The 2024 meta-analysis explicitly notes that due to variability between studies, the efficacy 'must be further explored through large randomized controlled trials' in humans [1]. Similarly, the Parkinson's study, which is paving the way for a human trial starting in 2025, emphasizes that lab tests did not reliably predict how well the cells would work in living animals, meaning we need better ways to predict human outcomes [3]. A major 2024 review of iPSC technology also highlights that while the field holds 'great promise,' developing safe and effective cell therapies requires overcoming challenges in quality control and standardization [5]. In short, the evidence strongly supports that iPSC therapy can be made safer (e.g., by removing tumor-forming cells), but we don't yet have enough human data to declare it safe for routine clinical use.

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2021 to 2025, 4 from 2024 or later, 5 in Q1 journals, collectively cited 318 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 46 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions